A8724
ADP-ribosyltransferase C3 from Clostridium botulinum
别名:
Botulinum neurotoxin C3, C3 Exoenzyme, C3 Exotoxin, C3 Transferase
Application
ADP-ribosyltransferase C3 from Clostridium botulinum may be used to study cellular signaling and G protein expression .
Biochem/physiol Actions
ADP-ribosyltransferase C3 from Clostridium botulinum ribosylates rho in eukaryotes in the presence of NAD. The ADP-ribosylating exoenzyme forms a single major 25 kDA (approx.) band with SDS electrophoresis. The enzyme labels 21-24 kDa proteins in tissues such as the human platelet membranes.
Ribosylates rho in eukaryotes in the presence of NAD.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
法规信息
新产品
此项目有
Jordi Farrés et al.
Blood, 122(1), 44-54 (2013-05-17)
Hematopoietic stem cells self-renew for life to guarantee the continuous supply of all blood cell lineages. Here we show that Poly(ADP-ribose) polymerase-2 (Parp-2) plays an essential role in hematopoietic stem/progenitor cells (HSPC) survival under steady-state conditions and in response to
J Michels et al.
Oncogene, 33(30), 3894-3907 (2013-09-17)
Poly(ADP-ribose) polymerase (PARP) inhibitors have raised high expectations for the treatment of multiple malignancies. PARP inhibitors, which can be used as monotherapies or in combination with DNA-damaging agents, are particularly efficient against tumors with defects in DNA repair mechanisms, in
Françoise Dantzer et al.
The FEBS journal, 280(15), 3508-3518 (2013-06-05)
Poly(ADP-ribose) polymerases (PARPs) are enzymes that transfer poly(ADP-ribose) (PAR) groups to target proteins, and thereby affect various nuclear and cytoplasmic processes. The activity of PARP family members, such as PARP1 and PARP2, is tied to cellular signalling pathways, and, through
E Andreas Larsson et al.
Journal of medicinal chemistry, 56(11), 4497-4508 (2013-05-16)
Tankyrases constitute potential drug targets for cancer and myelin-degrading diseases. We have applied a structure- and biophysics-driven fragment-based ligand design strategy to discover a novel family of potent inhibitors for human tankyrases. Biophysical screening based on a thermal shift assay
Jonathan Ledermann et al.
The Lancet. Oncology, 15(8), 852-861 (2014-06-03)
Maintenance monotherapy with the PARP inhibitor olaparib significantly prolonged progression-free survival (PFS) versus placebo in patients with platinum-sensitive recurrent serous ovarian cancer. We aimed to explore the hypothesis that olaparib is most likely to benefit patients with a BRCA mutation.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持